Introduction
The number of patients older than 65 years requiring end-stage renal disease (ESRD) therapy has increased markedly during the past two decades. For example, in the United States patients aged 65±74 years had adjusted incidence rates of 640 per million population in 1988, but 1296 per million population in 1997. Of the age group 75 years and older, the incidence rates were 512 (in 1988) and 1292 (in 1997) per million population. In contrast, patients aged 45±64 years had incidence rates of 329 and 557 per million population in 1988 and 1997, respectively [1 . ]. Data from the Department of Health and Human Services Health Care Financing Administration's REBUS data ®le show incidence counts of patients 65 years or older of 19 628 in 1990 but 36 400 in 1997 [1 . ]. In particular, the elderly diabetes mellitus population increased from 31% in 1990 to 41% in 1997. These patients often have a considerable number of comorbid diseases [2] .
The special needs of individual elderly patients differ considerably from those of younger patients. Haemodialysis treatment is the most widely used form of renal replacement therapy in the elderly. Continuous ambulatory peritoneal dialysis is of growing interest, especially in elderly patients, whereas renal transplantation in this group of ESRD patients is still controversial.
Better screening of elderly patients and improved survival rates as well as quality of life compared with dialysis treatment justi®es renal transplantation in the elderly population. All over the world, however, the gap between the supply and demand for cadaver kidneys has increased threefold within the past 10±15 years [3] .
Elderly patients are a heterogeneous group united by chronological but not necessarily biological age. The acceptance of elderly ESRD patients for renal transplantation varies considerably between industrialized countries and represents only a small number of individuals worldwide. Potential reasons for the small numbers of kidney transplantations in the elderly include the limited life expectancy of the recipient, the shortage of organs, reduced immunocompetence, unfavourable results under conventional immunosuppression in the 1970s, and high co-morbidity. Age per se, however, is no longer a risk factor with regard to renal transplantation.
Patient and graft survival
Age has a strong in¯uence on both patient and graft survival rates. The 5-year patient survival rates in Canada were 85% for transplanted patients 0±55 years of age compared with only 70% for patients over 55 years of age. The 5-year graft survival rate in patients older than 55 years was 55% compared with 67% for patients between 15 and 54 years of age [4] . Data from Norway showed 5-year survival rates for patients older than 70 years of 74% in patients receiving living related organs compared with 55% in cadaveric organ recipients. In recipients aged 55±70 years, 5-year patient survival rates after living related kidney transplantation was 72%, and after cadaveric organ transplantation it was 58%. Reasons for death were mainly cardiovascular (41%), cerebrovascular (18%), infectious (22%), malignant (12%) and miscellaneous (7%) diseases. Five-year graft survival rates in patients older than 70 years were 74% after living donor transplantation and 52% after cadaveric transplantation, respectively. In the group of recipients aged 55±70 years, the 5-year graft survival rate was 63% in living organ transplanted as compared with 51% in cadaveric organ transplanted patients. In patients older than 70 years the reasons for graft losses were patient death with a functioning graft in 83%, rejection in 15%, and recurrent disease in 2%. In the group of patients between 55 and 70 years, 66% of organs were lost as a result of patient death (P50.05), and 29% as a result of rejection (P50.05) [5] . Lufft et al. [6 . ] found that recipient age does not have an effect on graft survival. Graft losses were not signi®cantly more frequent in younger patients than in transplant recipients over the age of 65 years. Higher donor age had a signi®cantly negative impact on censored graft survival and proved to be an independent risk factor. Patient and graft survival after renal transplantation in the elderly have recently been summarized (V. Fabrizii, W.H. Ho È rl, in preparation).
Patient selection
The two main causes of morbidity and mortality after renal transplantation in the elderly are cardiovascular disease and infection. Therefore, before acceptance for the waiting list all older patients have to be screened intensively for cardiovascular disease and infectious foci. Furthermore, careful patient investigation is needed to exclude malignancy. . ] compared the results of 598 living donor recipients with those of 528 patients transplanted from cadaveric donors. A total of 74 living donor recipients and 54 cadaver organ recipients were transplanted from donors older than 55 years. In cadaver kidney transplant patients as well as in patients receiving organs from living donors graft survival was signi®cantly better using donors younger than 55 years. In patients without acute rejection episodes the 10-year graft survival with organs from younger donors was 94%, and with organs from older donors it was 93%. When one or more acute rejection episodes occurred, 10-year graft survival in the cohort of younger donors was 54%, but in the cohort of older donors it was only 39%. Kim et al. [11] reported that recipients of living donors older than 55 years had equivalent patient and graft survival rates compared with those who received kidneys from younger cadaveric donors. In the elderly donor group the serum creatinine level was signi®cantly higher but remained stable throughout the 3-year follow-up period. Age alone should not, therefore, be a sole factor for the exclusion of a potential donor.
Living related organ transplantation

Comparison between renal transplantation and haemodialysis
In the study by Bonal et al.
[12] patients aged 60±64 years had a better survival rate in the ®rst year on maintenance haemodialysis than after renal transplantation (97 versus 88%). Survival equalized in the third year (87% for both haemodialysis and renal transplant patients); after 5 years survival was superior in the transplanted patients compared with patients on haemodialysis (87 versus 77%). In patients aged 65±70 years, no differences were noted in 5-year survival rates (67% in patients on haemodialysis treatment, 66% for transplanted patients). When mortality was analysed, it was noted that patients on maintenance haemodialysis had a twofold greater risk of death compared with transplanted patients. Johnson et al. [13 . . ] compared patients older than 60 years treated by dialysis or renal transplantation. The overall mortality rates were similar after one year, but differed markedly after 3 and 5 years between the two treatment groups (92, 62 and 27% for the dialysis group; 98, 95 and 90% for the transplanted group).
Immunosuppression in the elderly
There is a high incidence of potentially lethal infections in elderly transplanted patients. This observation suggests a synergistic effect of immunosuppression and the impaired immune system in the elderly. Lymphocyte counts do not change with age, but CD4 T cells increase, as CD8 cells are reduced in the elderly [14]; IL-2 production also decreases with age. The activity of natural killer cells in the elderly has been discussed controversially. In haemodialysis patients older than 55 years, B and T cells, cytotoxic, IL-2 cytotoxic and active helper cells are all reduced [15] . CD4 cells did not differ between elderly and younger haemodialysis patients, whereas CD8 cells were signi®cantly reduced in elderly patients [16] .
Neutrophil phagocytosis, reactive oxygen species production and neutrophil bactericidal activity were recently assessed in three different age groups (21±26 years, 38± 56 years and 62±83 years). A signi®cant age-dependent reduction in the number of phagocytosed Escherichia coli per neutrophil and Staphylococcus aureus phagocytosis was observed. In the oldest individuals neutrophil bactericidal activity was impaired [17 . . ]. Immunosuppressive agents not only interfere with the immune response, but also with polymorphonuclear cell function, resulting in a further decrease of neutrophil function in the elderly [18] .
As fewer rejection episodes occur but the risk of infection is signi®cantly higher in the elderly, reduced immunosuppression after renal transplantation is recommended in these patients. ]. In the elderly, cyclosporine metabolism is reduced as a result of the reduction of the hepatic cytochrome P450 system, resulting in lower cyclosporine dosing. Corticosteroids are unfavourable for the skin and bones, particularly in the elderly. Increased prednisolone dose and older age are strongly associated with the development of post-transplant glucose intolerance [21] . In elderly transplanted patients, a quicker reduction of prednisolone is therefore recommended.
Elderly donors
The one-year graft survival of organs obtained from donors over 60 years of age is obviously comparable to kidneys obtained from younger donors. The incidence of acute tubular necrosis is also comparable between both groups [22] .
Old for old'
More kidneys from older donors have been accepted for transplantation during previous years because of the gap between supply and demand for cadaver kidneys. In the study by Alexander et al. [23] , approximately 524 recipients older than 55 years received organs from donors older than 55 years of age. No statistically signi®cant difference was found in the 2-year graft survival rates of organs from older donors (455 years) when transplanted into younger or older recipient age groups. Kidneys obtained from donors aged 19±30 years had the highest graft survival rates, with 84 and 73% at one and 3 years, respectively, and had a projected 10year survival rate of 45%. The one-year graft survival rate of kidneys from donors older than 70 years was 70%; the projected 10-year survival rate was only 20%. The quality of renal function one year post-transplant was better in older than in younger recipients. Older recipients were less often sensitized, were less likely to experience early rejection episodes, and more often received life-long function from their transplanted kidney [24] . In the study by Hariharan et al. [25] , 5year graft survival was 61.4% in the group of donors aged 19±50 years, 51.3% in recipients receiving organs from donors aged 51±60 years, and 42.7% with donors older than 60 years. Interestingly, transplantation of kidneys from older donors (460 years of age) led to better patient survival rates in older recipients (460 years of age) than in younger ones (560 years of age).
Allocating older donor kidneys to older recipients would make more younger donor kidneys available for younger recipients [24, 26] . According to donor and recipient age, 1269 cadaveric renal transplant recipients were divided into four groups (young for young, young for old, old for young and old for old). The long-term graft survival rates of kidneys from older donors (455 years of age) was signi®cantly reduced in young recipients compared with all other age combinations (8-year functional graft survival young for young' 52.2%;`young for old' 66.1%;`old for young' 22.5%;`old for old' 68.7%). The main reasons for graft loss were acute rejection (15.8%) and arterial occlusion (15.8%) in the`old for old' group. Acute or chronic rejection occurred in the`young for old' group in 10.3 or 11.5%, but in the`old for young' group in 33.7 or 24%. Death with a functioning graft appeared in 11.2% in the`young for young' group, in 26.9% in the`young for old' group, in 1.9% in the`old for young' group and in 26.2% in the`old for old' group, respectively. It was recommended that kidneys from older donors should be matched with old recipients [27 . ].
Old for young'
La Èngle et al. [28] compared the 3-year patient survival between donors younger than 30 years (87%), donors aged 30±60 years (96%), and donors older than 60 years (95%). Graft survival at 5 years was 90% for the ®rst group, 67% for the second group, and 39% for the third group. It was concluded that organs from elderly donors should not be transplanted into younger recipients. Lezaic et al. [29] reported in a study with 50 living related donors a higher incidence of delayed graft function as well as a higher sensitivity to immune, ischaemic or toxic in¯uences during the early posttransplant period in kidneys obtained from older donors. Chronic graft failure started earlier and progressed faster in recipients of older kidneys than of younger kidneys. It was concluded that grafts from donors older than 70 years should not be used for renal transplantation. The recommendations of further studies are that kidneys from elderly donors should be transplanted age-matched into elderly recipients [27 . ,30] . The arguments are summarized in Table 1 .
Quality of life
Improved rehabilitation, a better quality of life, a higher degree of functional autonomy and less co-morbidity after renal transplantation compared with haemodialysis therapy in the elderly was reported by Santiago-Delpin [31] and Bonal et al. [12] . Patients with high previous comorbidity and those of more advanced age should be evaluated individually, because their improvement with renal transplantation is less signi®cant and their morbidity and mortality is greater [32] .
Conclusion
Kidney transplantation in the elderly ESRD patient is associated with a low incidence of acute rejections, reduced immunocompetence and higher infection rates as well as metabolic derangements. Therefore, cautious, closely supervised immunosuppression and careful patient selection are the key elements for success in renal transplantation in the elderly [31] . On the other hand, donor age has been a consistent correlate of allograft outcome because of the appearance of glomerular, tubulointerstitial, and vascular lesions in the kidney [33] . The recipient should bene®t psychologically, intellectually, physically and socially for a suf®cient length of time to make donation worthwhile. Some 80 year olds may be healthier and have greater life expectancy than some 40 year olds, mandating proportionate access for all regardless of age [34 . . ].
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. of special interest Table 1 . Recommendations for renal transplantation in the elderly Exclusion of major cardiovascular and infectious risk factors as well as malignancy Elderly donors for elderly recipients Short cold ischaemia time Initial immunosuppression with prednisolone, mycophenolate-mofetil (or azathioprine) and antithymocyte globulin/antilymphocyte globulin Cyclosporine/tacrolimus therapy at adequate graft function (serum creatinine 5200 mmol/l) Reduction of immunosuppression as early as possible
